Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2032

Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.

Patents
1,150

Quick answer

1,150 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8263549

    C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8263632

    Aminopyridine derivatives having Aurora A selective inhibitory action

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8263662

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8263657

    Inhibitors against the production and release of inflammatory cytokines

    Institute of Medicinal Molecular Design, Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8263651

    Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors

    The Regents of the University of California · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8263650

    Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

    Jazz Pharmaceuticals, Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8263661

    Development of new selective estrogen receptor modulators

    The Regents of the University of California · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8263618

    8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists

    Theravance, Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8263605

    Modulators of muscarinic receptors

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8263606

    Spiro-oxindole compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8263588

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8263062

    Multi-arm polymer prodrugs

    Nektar Therapeutics · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8268344

    Particle-containing complex porous materials

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8268602

    Cellular and viral inactivation

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8268948

    Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom

    Nektar Therapeutics · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8268873

    Inhibitors of IMPDH enzyme

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8268825

    Method for the treatment of anthrax infections

    The Board of Regents for Oklahoma State University · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8268336

    Compositions containing aromatic aldehydes and their use in treatments

    SkinMedica, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8268323

    Conformationally stabilized HIV envelope immunogens

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8268776

    Macrocylic oximyl hepatitis C protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8268792

    Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases

    Reinhard Rettenberger · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8269026

    Lupane derivatives useful for treating HIV

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8269012

    Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8268999

    Tri-cyclic pyrazolopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8269014

    Thiophene analogues for the treatment or prevention of flavivirus infections

    Vertex Pharmaceuticals (Canada) Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8268615

    Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide

    The United States of America as represented by the Secretary of the Army · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8268799

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8268777

    Oximyl macrocyclic derivatives

    Enanta Pharmaceuticals, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8268786

    Anti-cancer tocotrienol analogues and associated methods

    First Tech International Limited · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8268811

    Thiazoles and pyrazoles useful as kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8268818

    Inhibitors of C-MET and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8268819

    Hexahydrooxazinopterine compounds

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8268851

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8268829

    Substituted pyrimidines useful as protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8268849

    Multifunctional Antioxidants and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8268863

    Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8269013

    Substituted pyrazole inhibitors of c-Met protein kinase

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8268890

    Method of treating ischemia/reperfusion injury with nitroxyl donors

    The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8268894

    Compositions and methods for the treatment of infectious diseases

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8268618

    Repressing endogenous CCR5 gene expression in cells using engineered zinc finger proteins

    Sangamo Biosciences, Inc. · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8273746

    Methods involving aldose reductase inhibitors

    The Board of Regents of the University of Texas System · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8273894

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8273780

    Polycyclic antagonists of lysophosphatidic acid receptors

    AMIRA PHARMACEUTICALS, INC. · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8273724

    Melanoma antigens and their use in diagnostic and therapeutic methods

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8273330

    Particulate materials

    Nektar Therapeutics · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8273343

    Protein-polymer conjugates

    PHARMAESSENTIA CORPORATION · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8273351

    Fc receptor binding proteins

    Syntonix Pharmaceuticals, Inc. · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8273339

    Polymer-based compositions and conjugates of antimicrobial agents

    Nektar Therapeutics · Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2032?

1,150 published patents in our USPTO index have expiration dates falling in calendar year 2032.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.